$NTLA
Intellia Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024123276 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $9.111M
YoY Change -24.02%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $30.50M
YoY Change 3.74%
% of Gross Profit
Research & Development $123.4M
YoY Change 8.52%
% of Gross Profit
Depreciation & Amortization $2.608M
YoY Change 13.89%
% of Gross Profit
Operating Expenses $123.4M
YoY Change 8.52%
Operating Profit -$144.8M
YoY Change 10.42%
Interest Expense $9.058M
YoY Change 2.0%
% of Operating Profit
Other Income/Expense, Net $9.058M
YoY Change 1.97%
Pretax Income -$135.7M
YoY Change 11.04%
Income Tax
% Of Pretax Income
Net Earnings -$135.7M
YoY Change 11.04%
Net Earnings / Revenue -1489.54%
Basic Earnings Per Share -$1.34
Diluted Earnings Per Share -$1.34
COMMON SHARES
Basic Shares Outstanding 101.8M 101.6M
Diluted Shares Outstanding 101.0M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $658.1M
YoY Change -23.01%
Cash & Equivalents $120.5M
Short-Term Investments $537.6M
Other Short-Term Assets $43.93M
YoY Change 36.44%
Inventory
Prepaid Expenses
Receivables $8.854M
Other Receivables $0.00
Total Short-Term Assets $710.9M
YoY Change -20.44%
LONG-TERM ASSETS
Property, Plant & Equipment $28.76M
YoY Change -14.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change -100.0%
Other Assets $16.84M
YoY Change -60.29%
Total Long-Term Assets $462.4M
YoY Change 32.18%
TOTAL ASSETS
Total Short-Term Assets $710.9M
Total Long-Term Assets $462.4M
Total Assets $1.173B
YoY Change -5.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.15M
YoY Change 269.97%
Accrued Expenses $51.21M
YoY Change -11.68%
Deferred Revenue $22.16M
YoY Change 65.99%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $105.7M
YoY Change 14.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $105.1M
YoY Change -7.85%
Total Long-Term Liabilities $105.1M
YoY Change -7.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $105.7M
Total Long-Term Liabilities $105.1M
Total Liabilities $210.7M
YoY Change 2.33%
SHAREHOLDERS EQUITY
Retained Earnings -$2.049B
YoY Change 34.22%
Common Stock $3.008B
YoY Change 17.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $962.6M
YoY Change
Total Liabilities & Shareholders Equity $1.173B
YoY Change -5.63%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$135.7M
YoY Change 11.04%
Depreciation, Depletion And Amortization $2.608M
YoY Change 13.89%
Cash From Operating Activities -$84.84M
YoY Change -16.32%
INVESTING ACTIVITIES
Capital Expenditures $1.279M
YoY Change -70.53%
Acquisitions
YoY Change
Other Investing Activities -$6.430M
YoY Change -107.67%
Cash From Investing Activities -$7.709M
YoY Change -109.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 82.19M
YoY Change 330.32%
NET CHANGE
Cash From Operating Activities -84.84M
Cash From Investing Activities -7.709M
Cash From Financing Activities 82.19M
Net Change In Cash -10.35M
YoY Change 272.45%
FREE CASH FLOW
Cash From Operating Activities -$84.84M
Capital Expenditures $1.279M
Free Cash Flow -$86.12M
YoY Change -18.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001652130
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#LicenseAndServiceMember
CY2023Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#LicenseAndServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#LicenseAndServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#LicenseAndServiceMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37766
dei Entity Registrant Name
EntityRegistrantName
INTELLIA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
36-4785571
dei Entity Address Address Line1
EntityAddressAddressLine1
40 Erie Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 130
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
285-6200
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
NTLA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
101848572
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120495000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
226748000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
537619000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
685475000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8854000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
36456000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
43934000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
49651000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
710902000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
998330000
CY2024Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
286567000
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
99864000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28763000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32760000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
100331000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
115375000
CY2024Q3 us-gaap Equity Method Investments
EquityMethodInvestments
0
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
11765000
CY2024Q3 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
46788000
CY2023Q4 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
42883000
CY2024Q3 us-gaap Assets
Assets
1173351000
CY2023Q4 us-gaap Assets
Assets
1300977000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
13145000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7452000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
51206000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
67017000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
19177000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
18599000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
22155000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
22140000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
105683000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
115208000
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
22607000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
38853000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
82446000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
96747000
CY2024Q3 us-gaap Liabilities
Liabilities
210736000
CY2023Q4 us-gaap Liabilities
Liabilities
250808000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
101796365
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
101796365
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
92997158
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
92997158
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
10000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
9000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3007810000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2710797000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3297000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2258000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2048502000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1658379000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
962615000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1050169000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1173351000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1300977000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9111000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11992000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45003000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38192000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
123380000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
113696000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
349434000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
326088000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30501000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29403000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
93385000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
87503000
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
153881000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
143099000
us-gaap Costs And Expenses
CostsAndExpenses
442819000
us-gaap Costs And Expenses
CostsAndExpenses
413591000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-144770000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-131107000
us-gaap Operating Income Loss
OperatingIncomeLoss
-397816000
us-gaap Operating Income Loss
OperatingIncomeLoss
-375399000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
12122000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
12740000
us-gaap Investment Income Interest
InvestmentIncomeInterest
37176000
us-gaap Investment Income Interest
InvestmentIncomeInterest
37373000
CY2024Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
-3064000
CY2023Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
0
us-gaap Gain Loss On Investments
GainLossOnInvestments
-29483000
us-gaap Gain Loss On Investments
GainLossOnInvestments
0
CY2024Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-3857000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-10905000
CY2024Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
CY2023Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
100000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9058000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8883000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7693000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
26368000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-135712000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-122224000
us-gaap Net Income Loss
NetIncomeLoss
-390123000
us-gaap Net Income Loss
NetIncomeLoss
-349031000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.34
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.34
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.38
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.99
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.99
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.96
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.96
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101002000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101002000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88645000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88645000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97842000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97842000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88204000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88204000
CY2024Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
4452000
CY2023Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
142000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
3423000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1649000
CY2024Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
0
CY2023Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
154000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
0
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
2240000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-131260000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-121928000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-386700000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-345142000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1050169000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1958000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34176000
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-821000
CY2024Q1 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
2132000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-107436000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
1036137000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1179000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1669000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
40861000
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-208000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-146975000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
971062000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2697000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
39619000
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
4452000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-135712000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
962615000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1235584000
CY2023Q1 ntla Contingent Consideration Paid To Rewrite Holders
ContingentConsiderationPaidToRewriteHolders
24126000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
755000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
27255000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2989000
CY2023Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
1794000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-103126000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1190843000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
465000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2051000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
36400000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1482000
CY2023Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
292000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-123681000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1104888000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4384000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
35352000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
142000
CY2023Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
154000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-122224000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1037414000
us-gaap Profit Loss
ProfitLoss
-390123000
us-gaap Profit Loss
ProfitLoss
-349031000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7719000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6510000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
76000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-5000
us-gaap Share Based Compensation
ShareBasedCompensation
114656000
us-gaap Share Based Compensation
ShareBasedCompensation
99007000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
14215000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
19590000
ntla Income Loss From Equity Method Investments Deferral Of Intra Entity Profit On Sales
IncomeLossFromEquityMethodInvestmentsDeferralOfIntraEntityProfitOnSales
-20967000
ntla Income Loss From Equity Method Investments Deferral Of Intra Entity Profit On Sales
IncomeLossFromEquityMethodInvestmentsDeferralOfIntraEntityProfitOnSales
6624000
us-gaap Gain Loss On Investments
GainLossOnInvestments
-29483000
us-gaap Gain Loss On Investments
GainLossOnInvestments
0
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-0
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-10905000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
100000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-27602000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2723000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4643000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
11806000
ntla Increase Decrease In Operating Right Of Use Assets
IncreaseDecreaseInOperatingRightOfUseAssets
-15044000
ntla Increase Decrease In Operating Right Of Use Assets
IncreaseDecreaseInOperatingRightOfUseAssets
-14148000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1476000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
836000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5364000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1419000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-14336000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3008000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-16231000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-37705000
ntla Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-13724000
ntla Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-12213000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-263685000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-301032000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4797000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12465000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
766471000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
754689000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
745270000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
689868000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25998000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-77286000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4832000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5604000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1669000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2051000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
183430000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23839000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-106253000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-354479000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
240353000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
535463000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
134100000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
180984000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120495000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
168027000
CY2024Q3 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
13605000
CY2023Q3 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
12957000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
134100000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
180984000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
374000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1552000
ntla Proceeds From Option Exercises Unpaid At Period End
ProceedsFromOptionExercisesUnpaidAtPeriodEnd
1002000
ntla Proceeds From Option Exercises Unpaid At Period End
ProceedsFromOptionExercisesUnpaidAtPeriodEnd
0
ntla Non Cash Trade In Of Property And Equipment
NonCashTradeInOfPropertyAndEquipment
99000
ntla Non Cash Trade In Of Property And Equipment
NonCashTradeInOfPropertyAndEquipment
0
CY2024Q3 ntla Shares Issued For Rewrite Contingent Consideration
SharesIssuedForRewriteContingentConsideration
0
CY2023Q3 ntla Shares Issued For Rewrite Contingent Consideration
SharesIssuedForRewriteContingentConsideration
24126000
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
820889000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3396000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
99000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
824186000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
785473000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
522000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
656000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
785339000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
CY2023 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
CY2024Q3 ntla Available For Sales Securities Noncurrent Maturing Beyond Year Five
AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive
0
CY2023Q4 ntla Available For Sales Securities Noncurrent Maturing Beyond Year Five
AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive
0
CY2024Q3 ntla Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
24325000
CY2023Q4 ntla Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
27411000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
20551000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
26615000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2677000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2063000
CY2024Q3 ntla Accrued Construction Costs
AccruedConstructionCosts
1349000
CY2023Q4 ntla Accrued Construction Costs
AccruedConstructionCosts
6891000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2304000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4037000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
51206000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
67017000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
36456000
ntla Increase In Accounts Receivables
IncreaseInAccountsReceivables
19422000
ntla Decrease In Accounts Receivables
DecreaseInAccountsReceivables
47024000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8854000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
60993000
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
0
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-16231000
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
44762000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3768000
ntla Increase In Accounts Receivables
IncreaseInAccountsReceivables
15287000
ntla Decrease In Accounts Receivables
DecreaseInAccountsReceivables
12564000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6491000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
63771000
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
0
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-37705000
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
26066000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
16231000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
31081000
CY2024Q3 us-gaap Capitalized Contract Cost Gross
CapitalizedContractCostGross
0
CY2024Q3 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures Fair Value Disclosure
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure
5740000
CY2023Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures Fair Value Disclosure
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure
10000000
CY2024Q3 us-gaap Other Investments
OtherInvestments
24213000
CY2023Q4 us-gaap Other Investments
OtherInvestments
14760000
CY2024Q3 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
13605000
CY2023Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
13605000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
3230000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
4518000
CY2024Q3 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
46788000
CY2023Q4 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
42883000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39619000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
35352000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
114656000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
99007000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
4041753
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
50.4
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
3326772
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
33.89
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
1335350
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
51.56
ntla Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
582581
ntla Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue
43.5
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
5450594
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
40.77
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.042
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.044
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.758
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.763
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.787
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5458999
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
50.38
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
35922000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
918161
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
30.72
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
371736
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
15.69
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
526473
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
71.23
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5478951
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
47.43
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M7D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11250000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4096828
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
47.42
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M3D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11250000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-135712000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-122224000
us-gaap Net Income Loss
NetIncomeLoss
-390123000
us-gaap Net Income Loss
NetIncomeLoss
-349031000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101002000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101002000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88645000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88645000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97842000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97842000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88204000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88204000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.34
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.34
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.38
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.99
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.99
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.96
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.96
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10930000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10930000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9516000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9516000
CY2024Q3 ntla Rule10 B51 Arr Modified1 Flag
Rule10B51ArrModified1Flag
true

Files In Submission

Name View Source Status
0000950170-24-123276-index-headers.html Edgar Link pending
0000950170-24-123276-index.html Edgar Link pending
0000950170-24-123276.txt Edgar Link pending
0000950170-24-123276-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ntla-20240930.htm Edgar Link pending
ntla-20240930.xsd Edgar Link pending
ntla-ex31_1.htm Edgar Link pending
ntla-ex31_2.htm Edgar Link pending
ntla-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
ntla-20240930_htm.xml Edgar Link completed
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable